- Home
- SNX vs BBIO Comparison
SNX vs BBIO Comparison
Compare SNX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNX | BBIO |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 14.4B |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNX | BBIO |
|---|---|---|
| Price | $149.37 | $74.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $169.00 | $75.75 |
| AVG Volume (30 Days) | 604.7K | ★ 2.0M |
| Earning Date | 01-08-2026 | 10-29-2025 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 18.98 | N/A |
| EPS | ★ 9.21 | N/A |
| Revenue | ★ $60,973,509,000.00 | $353,780,000.00 |
| Revenue This Year | $7.25 | $128.44 |
| Revenue Next Year | $4.50 | $76.14 |
| P/E Ratio | $16.91 | ★ N/A |
| Revenue Growth | 6.94 | ★ 62.46 |
| 52 Week Low | $92.23 | $25.34 |
| 52 Week High | $167.76 | $75.24 |
Technical Indicators
Market Signals| Indicator | SNX | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 65.80 |
| Support Level | $152.97 | $70.35 |
| Resistance Level | $158.68 | $75.10 |
| Average True Range (ATR) | 3.15 | 2.20 |
| MACD | 0.18 | -0.16 |
| Stochastic Oscillator | 5.05 | 82.81 |
Price Performance
Historical ComparisonAbout SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.